FIELD: medicine.;SUBSTANCE: invention relates to medicine, namely to gynecology, and can be used to predict reproductive health disorders in women of fertile age. Method comprises determining the percentage of CD3+CD8+, CD16+CD56+, CD19+ cells among blood lymphocytes, serum levels of IgG immunoglobulins, IgG-autoantibodies to β2 glycoprotein-1, prolactin, estradiol, total thyroxine, cortisol. Integral Markers of the Reproduction Violations (IMRV1 and IMRV2) are calculated by the formulas: IMRV1=0.257*[CTL]+0.266*[EC]+0.122*[V]+0.107*[IgG]+0.209*[AT β2-GP], where CTL is % of CD3+, CD8+cells among blood lymphocytes, EC is % of CD16+CD56+cells among blood lymphocytes, V is % of CD19+cells among blood lymphocytes, IgG is the level of immunoglobulin class G in mg/ml serum, AT β2-GP is the level of IgG-autoantibodies to β2-glycoprotein-1 in the ED/ml of blood serum. IMRV2=0.341*[PL]+0.257*[E2]+0.184*[T4]-0.153*[CT], where PL is the level of prolactin in nmol/l serum; E2 is the level of estradiol in pmol/l of blood serum; T4 is the level of total thyroxin in nmol/l serum; CT is the level of cortisol in nmol/d. For values of IMRV111.5 and/or IMRV285, women are considered at risk for reproductive health problems.;EFFECT: use of this method allows predicting reproductive health disorders in women of fertile age during the preclinical period.;1 cl, 2 dwg, 2 ex
展开▼